Structure Therapeutics CFO shares withheld for taxes

Accepted by SEC EDGAR 03/05/2026 - 06:20 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Structure Therapeutics Inc. reported an insider equity transaction by its Chief Financial Officer, Yoon JunMarch 3, 2026, 22,305 Ordinary Shares were disposed of through shares withheld by the company to cover income tax obligations tied to the vesting of a restricted share unit award at $20.99 per share, a tax-withholding disposition rather than an open-market sale. Following this, Yoon Jun directly held 1,297,571 Ordinary Shares and indirectly held 1,554,586 Ordinary Shares through The Yoon Family Trust. The company notes that its Ordinary Shares may be represented by ADSs, with each ADS equal to three Ordinary Shares.

Insider Trade Summary

Exercise Price or Tax Liability: 22,305 shares

Exercise Price or Tax Liability 1 txn

Insider Yoon Jun

Role CHIEF FINANCIAL OFFICER

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Ordinary Shares	22,305	$20.99	$468K
Holding	Ordinary Shares	--	--	--

Holdings After Transaction: Ordinary Shares — 1,297,571 shares (Direct); Ordinary Shares — 1,554,586 shares (Indirect, See footnote)

Holdings Before and After: Ordinary Shares, 1,319,876 to 1,297,571 shares (Direct)

Footnotes (3)

1. F1. The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents three Ordinary Shares of the Issuer.
2. F2. Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of a restricted share unit award.
3. F3. By Jun Sik Yoon and Hayung Yang Yoon, Trustees of The Yoon Family Trust, dated December 11, 2019.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Structure Therapeutics (GPCR) report for its CFO?

Structure Therapeutics reported that CFO Yoon Jun had 22,305 Ordinary Shares withheld on March 3, 2026 to satisfy income tax obligations from a restricted share unit vesting, recorded as a tax-withholding disposition rather than an open-market trade.

How many Structure Therapeutics (GPCR) shares were involved and at what price?

The transaction involved 22,305 Ordinary Shares at $20.99 per share. These shares were withheld by the issuer to cover income taxes arising from the vesting of a restricted share unit award, not sold on the open market by the CFO.

Was the Structure Therapeutics (GPCR) Form 4 a market sale by the CFO?

No, it was not a market sale. The Form 4 shows a tax-withholding disposition, where 22,305 Ordinary Shares were withheld by Structure Therapeutics to satisfy the CFO’s income tax obligations related to restricted share unit vesting.

What are Yoon Jun’s Structure Therapeutics (GPCR) share holdings after the transaction?

After the transaction, CFO Yoon Jun directly held 1,297,571 Ordinary Shares. He also indirectly held 1,554,586 Ordinary Shares through The Yoon Family Trust, where he and Hayung Yang Yoon serve as trustees, according to the disclosure.

How are Structure Therapeutics (GPCR) Ordinary Shares represented by ADSs?

Structure Therapeutics states that its Ordinary Shares may be represented by American Depositary Shares (ADSs). Each ADS represents three Ordinary Shares, providing a ratio investors can use when comparing ADS holdings to the company’s underlying ordinary equity.

What entity holds Yoon Jun’s indirect Structure Therapeutics (GPCR) shares?

The indirect holdings are held by The Yoon Family Trust, dated December 11, 2019. The Form 4 notes that Jun Sik Yoon and Hayung Yang Yoon serve as trustees of this trust, which owns 1,554,586 Ordinary Shares of Structure Therapeutics.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Yoon Jun

(Last) (First) (Middle)

C/O STRUCTURE THERAPEUTICS INC.

601 GATEWAY BLVD., SUITE 900

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Structure Therapeutics Inc. [ GPCR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF FINANCIAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares(1)	03/03/2026		F		22,305(2)	D	$20.99	1,297,571	D
Ordinary Shares(1)								1,554,586	I	See footnote(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents three Ordinary Shares of the Issuer.

2. Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of a restricted share unit award.

3. By Jun Sik Yoon and Hayung Yang Yoon, Trustees of The Yoon Family Trust, dated December 11, 2019.

	/s/ Jun Yoon	03/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.